5-HT systems and anxiety: Multiple mechanisms in the elevated X-maze

Polish Journal of Pharmacology

Volumn 48, Issue 1, 1996, Pages 1-12

  McCreary, Andrew C ^a   McBlane, James W ^a   Spooner, H Ann ^a   Handley, Sheila L ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

5 hydroxytryptamine; anxiety; anxiolytic; elevated X maze; factor analysis; review

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; SEROTONIN; SEROTONIN 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; DRUG EFFECT; FOREBRAIN; MAZE TEST; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONINERGIC NERVE; TRANQUILIZING ACTIVITY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANXIETY; FACTOR ANALYSIS, STATISTICAL; MAZE LEARNING; MICE; NEURONS; RATS; SEROTONIN;

EID: 0029886275     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Artigas F.: 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacoi. Sci., 1994, 14, 262.
2. Audi E. A., de Aguiar J. C., Graeff F. G.: Mediation by serotonin of the antiaversive effect of zimeldine and propranolol injected into the dorsal midbrain central grey. J. Psychopharmacol., 1988, 2, 26-32.
3. Bandler R., Depaulis A.: Midbrain periaqueductal gray control of defensive behaviour in the cat. In: The Midbrain Periaqueductal Gray Matter. Functional, Anatomical, and Neurochemical Organisation. Eds. Depaulis A., Bandler R., Plenum Press, New York, 1991, 175-198.
4. Beckett S. R. G., Marshall P. W., Marsden C. A.: Intra-periaqueductal grey administration of mCPP potentiates a chemically-induced defence response. Brit. J. Pharmacol., 1992, 107, 8P.
5. Blanchard D. C., Blanchard R. J., Rogers R. J.: Risk assessment in animal models of anxiety. In: Animal Models in Psychopharmacology. Eds. Olivier B., Mos J., Slangen J. L., Birkhauser, Basle, 1991, 117-134.
6. 1A receptors causes amnesia and anxiolytic-like but not antidepressantiike effects in the rat. Eur. J. Pharmacol., 1993, 234, 215-221.
7. 1A receptors in the anticonflict effect of ipsapirone in rats. Neuropharmacology, 1991, 30, 703-709.
8. Chopin P., Briley M.: Animal models of anxiety: the effect of compounds that modify scrotonergic function. Trends Pharmacol. Sci., 1987, 8, 383-388.
9. Coplan J. D., Gorrnan J. M., Klein D. E.: Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology, 1992, 6, 189-200.
10. 2 receptors. Psychopharmacology, 1987, 93, 502-506.
11. 1A ligands in the elevated X-maze and effects of dorsal raphe lesions. Psychopharmacology, 1992, 106, 484-490.
12. Cruz P. M., Frei F., Graeff F. G.: Ethopharmacological analysis of rat behaviour on the elevated plusmaze. Pharmacol. Biochem. Behav., 1994, 49, 171-176.
13. Dawson G. R., Tricktebank M. D.: Use of the elevated plus maze in the search for novel anxiolytics. Trends Pharmacol. Sci., 1995, 16, 33-36.
14. Deakin J. F. W.: Three distinct roles of 5-HT in anxiety, panic and depression. In: Psychopharmacology of Depression. Eds. Montgomery S. A., Corn T. H., Oxford Medical Publications, Oxford, 1994, 87-101.
15. Deakin J. F. W., Graeff F. G.: 5-HT and mechanisms of defence. J. Psychopharmacol., 1991, 5, 305-315.
16. De Boer M., Op Den Velde W., Falger P. J., Hovens J. E-, De Groen J. H., Van Duijn H.: Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother. Psychosom. Med. Psychol., 1992, 57, 158-163.
17. 1A agonists. In: Animal Models of Anxiety and Depression. Eds. Stahl S. M., Gastpar M., Keppel-Hesselink J. M., Raven Press, New York, 1992, 55-81.
18. 1A autoreceptors in the raphe nuclei. Trends Pharmacol. Sci., 1986, 7, 212-214.
19. Falter U., Gower A. J., Gobert J.: Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behav. Pharmacol., 1992, 3, 123-128.
20. File S. E.: The biological basis of anxiety. In: Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders. Eds. Meltzer H. Y., Nerozzi D., Elsevier, 1991, 159-165.
21. Graeff F. G.: Role of 5-HT in defensive behaviour and anxiety. Rev. Neurosci., 1994, 4, 181-211.
22. Graeff F. G,: Neuroanatomy and neurotransmitter regulation of defensive behaviours and related emotions in mammals. Braz. J. Med. Biol. Res., 1994, 27, 811-829.
23. Graeff F. G., Silveira M. C. L., Nogueira R. L., Audi E. A., Oliveira R. M. W.: Role of the amygdala and periaqueductal grey in anxiety and panic. Behav. Brain Res., 1993, 58, 123-131.
24. Green S.: Benzodiazepines, putative anxiolytics and animal models of anxiety. Trends Neurosci., 1991, 14, 101-104.
25. Handley S.: Serotonin in animal models of anxiety: the importance of stimulus and response. In: Serotonin, Sleep and Mental Disorder. Eds. Idzikowski C., Cowen P. J., Wrightson Biomedica, Petersfield, 1991, 89-115.
26. Handley S. L.: 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther., 1995, 66, 103-148.
27. Handley S. L., McBlane J. W.: 5-HT - the disengaging transmitter? J. Psychopharmacol., 1991, 5, 322-326.
28. Handley S. L., McBlane J. W.: 5-HT drugs in animal models of anxiety. Psychopharmacology, 1993, 112, 13-20.
29. Handley S. L., McBlane J. W.: An assessment of the elevated X-maze for studying anxiety and anxietymodulating drugs. J. Pharmacol. Toxicol. Method., 1993, 29, 129-138.
30. Handley S. L., Mithani S.: Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmied. Arch. Pharmacol., 1984, 327, 1-5.
31. Handley S. L., McBlane J. W., Critchley M. A. E. Njung'e K.: Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav. Brain Res., 1993, 58, 203-210.
32. Harman H.: Modem Factor Analysis. University of Chicago Press, Chicago, 1976.
33. Hodges H., Green S., Glenn B.: Evidence that the amygdala is involved in benzodiazepine and scrotonergic effects on punished responding but not on discrimination. Psychopharmacology, 1987, 92, 491-504.
34. Hogg S., Andrews N., File S. E.: Contrasting behavioural effects of 8-OH-DPAT in the dorsal raphe nucleus and ventral hippocampus. Neuropharmacology, 1994, 33, 343-348.
35. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R., Humphrey P. A.: VII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev., 1994, 46, 157-203.
36. Humphrey P. P. A., Hartig P., Hoyer D.: A proposed new nomenclature for 5-HT receptors. Trends Phar-macol Sci., 1993, 14, 233-236.
37. Iversen S. D.: 5-HT and anxiety. Neuropharmacology, 1984, 23, 1553-1560.
38. Jacobs B. L., Fornal C. A.: Activity of brain serotonergic neurons in the behaving animal. Pharmacol. Rev., 1991, 43, 563-585.
39. Jacobs B. L., Fomal C. A.: 5-HT and motor control: a hypothesis. Trends Neurosci., 1993, 16, 346-352.
40. 3 receptors. Psychopharmacology, 1989, 97, 489-495.
41. 1C) receptors on periaqueductal gray aversion. Eur. J. Pharmacol., 1989, 161, 219-221.
42. 1C receptors in the serotonergic control of periaqucductal gray induced aversion in rats. Psychopharmacology, 1990, 100, 373-376.
43. Jenck F., Broekkamp C. L. E., Van Delft A. M. L.: The effect of antidepressants on aversive PAG stimulation. Eur. J. Pharmacol., 1990, 177, 201-204.
44. 1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurones in the rat? J. Pharmacol. Exp. Ther. 1995, 272, 920-929.
45. Kabuto H., Yokoi I., Iwaya K., Mori A.: Monoamine release in the rat striatum is induced by delta-guanidinovaleric acid and inhibited by GABA agonists. Life Sci., 1995, 56, 1741-1748.
46. Kataoka Y., Shibata K., Miyazaki A., Inoue Y., Tominaga K., Koizumi S., Ueki S. Niwa M.: Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine 1A agonistic anxiolytic. Neuropharmacology, 1991, 30, 475-480.
47. 1C receptors and their therapeutic relevance. Curr. Opin. Invest. Drug., 1993, 2, 317-362.
48. Kostowski W., Plaźnik A., Stefaŕiski R.: Intra-hippocampal buspirone in animal models of anxiety. Eur. J. Pharmacol., 1989, 168, 393-396.
49. Lister R. G.: The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 1987, 92, 180-185.
50. Lorrain D. S., Hull E. M.: Nitric oxide increases dopamine and serotonin release in the medial preoptic area. Neuroreport, 1993, 5, 87-89.
51. Lucas J. J., Hen R.: New players in the 5-HT receptor field: genes and knockouts. Trends Pharmacol. Sci., 1995, 16, 246-252.
52. McBlane J. W., Handley S. L.: Effects of two Stressors on behaviour in the elevated X-maze: preliminary investigation of their interaction with S-OH-DPAT. Psychopharmacology, 1994, 116. 173-182.
53. 2 receptors of the inferior colliculus in aversive states induced by the exposure of rats to the elevated plus-maze test. Behav. Pharmacol., 1995, 6, 413-417.
54. Miller H., Deakin J. F. W., Anderson I.: Acute tryptophan depiction increases panic anxiety in panic disorder patients. J. Psychopharmacol., 1995, 9 (Suppl.), A18.
55. Montgomery S. A., Manceaux A.: Fluvoxamine in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 1992, 7 (Suppl. 1), 5-9.
56. Moser P. C.: An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology, 1989, 99, 48-53.
57. Nashold R. S., Wilson N. P., Slaughter C. S.: Sensations evoked by stimulation of the midbrain in man. J. Neurosurg., 1969, 30, 14-24.
58. Nie N. H., Hull C. H., Jenkins J. G.: Statistical Package for the Social Sciences. McGraw-Hill, New York, 1975.
59. Njung'e K., Critchley M. A. E., Handley S. L.: Effects of beta-adrenoceptor agonists and antagonists in the elevated X-maze anxiety model. J. Psychopharmacol., 1992, 7, 173-180.
60. Nutt D., Lawson L.: Panic attacks, an overview of models and mechanisms Brit. J. Psychiat., 1992, 160, 165-178.
61. Ohta K., Araki N., Shibata M., Komasumoto S., Shimazu K., Fukuuchi Y.: Presynaptic glutamate receptors modulate in vivo release and metabolism of striatal dopamine, noradrenaline and 5-hydroxytryptamine involvement of both NMDA and AMPA/ kainate subtypes. Neurosci. Res., 1994, 21, 83-89.
62. Fellow S., Chopin P., File S., Briley M.: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth., 1985, 14, 149-167.
63. Płaźnik A., Danysz W., Kostowski W.: Some behavioural effects of microinjections of noradrenaline and serotonin into the hippocampus of the rat. Physiol Behav., 1983, 31, 625-631.
64. Plaźnik A., Kostowski W., Stetanski R.: Limbic mechanisms of anxiolytics acting on 5-HT receptors. Pol. J. Pharmacol., 1994, 46, 473-477.
65. Power A. C., Cowen P. J.: Fluoxetine and suicidal behaviour, some theorctical aspects of a controversy. Brit. J. Psychiat., 1992, 161, 735-741.
66. Redgrave P., Dean P.: Tectal inputs to the PAG. In: The Periaqueductal Grey Matter. Eds. Depaulis A., Bandler R., Plenum Press, New York, 1991, 199-211.
67. Rex A., Marsden C. A., Fink H., Effect of diazepam on cortical 5-HT release and behaviour in the guineapig on exposure to the elevated plus maze. Psychopharmacology, 1993, 110, 490-496
68. Rodgers R. J., Cole J. C.: Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors. Physiol. Behav., 1993, 53, 383-388.
69. Rodgers R. J., Cole J. C.: The elevated plus-maze: pharmacology, methodology and ethology. In: Ethology and Psychopharmacology. Eds. Cooper S. J., Hendrie C. A., Wiley, Chichester, 1994, 9-44.
70. Rodgers R. J., Cole J. C., Cobain M. R. Daly P., Doran P. J., Eclls J. R., Wallis P.: Anxiogcnic-like effects of flupraxine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT. CGS12066B, TFMPP and mCPP. Behav. Pharmacol., 1992, 3, 621-634.
71. 1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur. J. Pharmacol., 1993, 249, 341-351.
72. 1A Agonists and 5-HT3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Eds. Rodgers R. J., Cooper S. J., Wiley, New York, 1991, 366-376.
73. Shepherd J., Grewal S., Cobain M.: Novel ethological models of anxiety in the rat and ferret. In: Ethology and Psychopharmacology. Eds. Cooper S. J.. Hendrie C. A., Wiley, Chichester, 1994, 59-84.
74. Silveira M. C. L., Graeff F. G., Sandner G.: Regional distribution of Fos-like immunoreactivity in the rat brain after exposure to fear-inducing stimuli. Braz. J. Med. Biol. Res., 1994, 27, 1077-1081.
75. Soubrié P.: Reconciling the role of central serotonin neurons in human and animal behavior. Behav. Brain Sci., 1986, 9, 319-364.
76. 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology, 1988, 27, 707-715.
77. Stefański R., Palejko W., Bidziński A., Kostowski W., Płaźnik A.: Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists. Neuropharmacology, 1993, 32, 977-985.
78. 3 receptor antagonists. Neuropharmacology, 1993, 32, 987-993.
79. Stein L., Wise C. D., Berger B. D.: Antianxiety acions of benzodiazepines: decrease in activity of serotonin neurones in the punishment system. In: The Benzodiazepines. Eds. Garattini S., Mussini E., Randall I. O., Raven Press, New York, 1973, 299-326.
80. Thiébot M-H., Hamon M., Soubrié P.: The involvement of nigral serotonin innervation in the control of punishment-induced behavioral inhibition in rats. Phamacol. Biochem. Behav., 1983, 19, 225-229.
81. Tomkins D. M., Costall B., Kelly M. E.: Action of ritanscrin and DOI on the elevated X-maze. Psychopharmacology, 1990, 101, S57.
82. Treit D., Robinson A., Rotzinger S., Pesold C.: Anxiolytic effects of serotonergic interventions in the shock-probe burying test and the elevated plus-maze test. Behav. Brain Res., 1993, 54, 23-34.
83. Trendelenburg A-U., Trendelenburg M., Starke K., Limberger N.: Release-inhibiting alpha2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with alpha2-autoreceptors. Naunyn-Schmied. Arch. Pharmacol., 1994, 349, 25-33.
84. Viana M. B., Tonaz C., Graeff F. G.: The elevated T-maze: a new animal model of anxiety and memory. Pharmacol. Biochem. Behav., 1994, 28, 697-705.
85. Whitton P., Curzon G.: Anxiogenic-like effect of infusing 1-(3-ehlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology, 1990, 100, 138-140.
86. Wuttke W., Demling J., Fuchs E., Mansky T., Keck H., Lamberts R., Graf M.: Norepinephrine-mediated effects of GABA on LH release. In: Catecholamines: Neuropharmacology and Central Nervous System. Eds, Usdin E., Carlsson A., Dahlstrom A., Engel J., Liss, New York, 1984, 463-468.
87. Yu Z. J., Wecker L.: Chronic nicotine administration differentially affects neurotransmitter release from rat striatal slices. J. Neurochem., 1994, 63, 186-194.